"Unsere Kernkompetenz ist die internistische Rheumatologie. Hier stehen wir für hohe medizinische Qualität und erfreuen uns als großes MVZ im Herzen Hamburgs überregionaler Bekanntheit. Zusätzlich bieten wir auch eine immunologische Beratung sowie die Abklärung und Therapie von Immundefekten an. Aktuell besteht unser Ärzteteam aus 13 internistischen Rheumatologen, 3 Laborärzten sowie weiteren Ärzten im Bereich der Forschung. Wir zählen damit zu den größten rheumatologischen Praxen in ganz Deutschland. Sie finden uns an zwei Standorten in Hamburg. Der Hauptstandort befindet sich in der Mönckebergstraße mit Blick auf das Rathaus. Unser zweiter etwas kleinerer Standort befindet sich am S-Bahnhof Blankenese."

During the past decade, HRF Hamburger Rheuma Forschungszentrum conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 8 clinical trials were completed, i.e. on average, 61.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "HRF Hamburger Rheuma Forschungszentrum" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "R-Pharm International, LLC" with 3 trials sponsored, "Fresenius Kabi SwissBioSim GmbH" with 1 trials sponsored and "Janssen Pharmaceutica N.V., Belgium" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "HRF Hamburger Rheuma Forschungszentrum" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "Hexal AG" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator and "Mene Research" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "HRF Hamburger Rheuma Forschungszentrum" are "Rheumatoid Arthritis" (4 trials), "Arthritis, Psoriatic" (3 trials), "Psoriatic Arthritis" (2 trials), "Arthritis, Rheumatoid" (1 trials) and "Axial Spondyloarthritis" (1 trials). Many other conditions were trialed in "HRF Hamburger Rheuma Forschungszentrum" in a lesser frequency.

Most popular intervention types in "HRF Hamburger Rheuma Forschungszentrum" are "Drug" (12 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Guselkumab" (2 trials), "Ixekizumab" (2 trials), "Nipocalimab" (2 trials) and "Adalimumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "HRF Hamburger Rheuma Forschungszentrum" are 13 trials for "All" genders.

Currently, there are NaN active trials in "HRF Hamburger Rheuma Forschungszentrum". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in HRF Hamburger Rheuma Forschungszentrum, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in HRF Hamburger Rheuma Forschungszentrum, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".